Accepted Manuscript

Current progress toward a better understanding of drug disposition within the lungs: summary proceedings of the 1st Workshop on Drug Transporters in the Lungs

Carsten Ehrhardt, Per Bäckman, William Couet, Chris Edwards, Ben Forbes, Markus Fridén, Mark Gumbleton, Ken-ichi Hosoya, Yukio Kato, Takeo Nakanishi, Mikihisa Takano, Tetsuya Terasaki, Ryoko Yumoto

PII: S0022-3549(17)30243-5
DOI: 10.1016/j.xphs.2017.04.011
Reference: XPHS 733

To appear in: Journal of Pharmaceutical Sciences

Received Date: 25 February 2017
Revised Date: 7 April 2017
Accepted Date: 7 April 2017


This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Current progress toward a better understanding of drug disposition within the lungs: summary proceedings of the 1st Workshop on Drug Transporters in the Lungs

Carsten Ehrhardt¹*, Per Bäckman², William Couet³, Chris Edwards⁴, Ben Forbes⁵, Markus Fridén⁶, Mark Gumbleton⁷, Ken-ichi Hosoya⁸, Yukio Kato⁹, Takeo Nakanishi¹⁰, Mikihisa Takano¹¹, Tetsuya Terasaki¹², Ryoko Yumoto¹¹

¹School of Pharmacy and Pharmaceutical Sciences, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland
²Mylan Global Respiratory Group, Sandwich, UK
³Inserm U1070, Université de Poitiers, UFR Médecine-Pharmacie, CHU Poitiers, Poitiers, France
⁴Refractory Respiratory Inflammation DPU, GlaxoSmithKline Medicines Research Centre, Stevenage, Hertfordshire, United Kingdom
⁵Institute of Pharmaceutical Science, King’s College London, London, United Kingdom
⁶Translational PKPD Group, Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden; Respiratory, Inflammation and Autoimmunity Innovative Medicines, AstraZeneca R&D Gothenburg, Mölndal, Sweden.
⁷Experimental Therapeutics, School of Pharmacy and Pharmaceutical Sciences, Cardiff University Cardiff, Wales, United Kingdom
⁸Department of Pharmaceutics, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, Japan
⁹Department of Molecular Pharmacotherapeutics, Faculty of Pharmaceutical Sciences, Kanazawa University, Kanazawa, Japan
¹⁰Department of Membrane Transport and Biopharmaceutics, Faculty of Pharmaceutical Sciences, Kanazawa University, Kanazawa, Japan
¹¹Graduate School of Biomedical & Health Sciences, Hiroshima University, Hiroshima, Japan
¹²Graduate School of Pharmaceutical Sciences, Tohoku University, Miyagi, Japan

Corresponding author

Dr. Carsten Ehrhardt, School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, Panoz Institute, Dublin 2, Ireland, tel.: +353-1-896-2441, email: ehrhardc@tcd.ie
ABSTRACT

The School of Pharmacy and Pharmaceutical Sciences at Trinity College Dublin hosted the 1st Workshop on Drug Transporters in the Lungs in September 2016 to discuss the impact of transporters on pulmonary drug disposition and their roles as drug targets in lung disease. The workshop brought together about 30 scientists from academia and pharmaceutical industry from Europe and Japan and addressed the primary questions: What do we know today, and what do we need to know tomorrow about transporters in the lung? The three themes of the workshop were: (1) techniques to study drug transporter expression and actions in the lungs; (2) drug transporter effects on pulmonary pharmacokinetics – case studies; and (3) transporters as drug targets in lung disease.

Some of the conclusions of the workshop were: suitable experimental models that allow studies of transporter effects are available; data from these models convincingly show a contribution of both uptake and efflux transporters on pulmonary drug disposition; the effects of transporters on drug lung PK is now better conceptualised; some transporters are associated with lung diseases. However, more work is needed to establish which of the available models best translate to the clinical situation.

KEYWORDS: Absorption; Computational ADME; Efflux pumps; In vitro models; Organic cation transporters; P-glycoprotein; Peptide Transporters; Pulmonary delivery/absorption; ABC Transporters; Organic anion-transporting polypeptide transporters
LIST OF ABBREVIATIONS

ASP⁺, 4-(4-(dimethylamino) styryl)-N-methylpyridinium iodide; BAL, broncho-alveolar lavage; BCRP, breast cancer resistance protein; CDF, carboxy-dichlorofluorescein; COX, cyclooxygenase; ECF, extra-cellular fluid; ELF, epithelial lining fluid; HPAEpiC, human primary alveolar epithelial cells; HTEpiC, human tracheal epithelial cells; IPRL, isolated and perfused rat lung; LC-MS/MS, liquid chromatography–linked tandem mass spectrometry; MDR, multidrug resistance; MRP, multidrug resistance-associated protein; OAT, organic anion transporter; OATP, organic anion transporting polypeptide; OCT, organic cation transporter; NHBE, normal human bronchial epithelial cells; PEPT, peptide transporter; PG, prostaglandin; P-gp, P-glycoprotein; PBPK, physiologically based pharmacokinetics; PK, pharmacokinetics; PKC, protein kinase C; SLC, solute carrier; SV, simian virus; \( V_{u,lung} \), volume of distribution in the lung
INTRODUCTION

In pre-clinical drug development, drug transporter interactions are routinely studied in epithelia of the intestine, liver and kidney as well as the endothelium of the blood–brain barrier. Transporter effects in pulmonary drug disposition have been hypothesised for several years (reviewed, e.g. in 14, 15, 31 and 32). The vast majority of data that are available were generated using organotypic in vitro or ex vivo models and are consistent with the idea that drug absorption from the lungs is not exclusively mediated by passive diffusion. These initial studies confirmed the expression of drug transporters in lung tissues in situ and/or demonstrated transporter-related effects in cultured cells, but the translation of these data into clinical practice is still missing.

It was the aim of this workshop to bring together a group of international experts who shall summarise and discuss the available information on lung drug transporters and to find a consensus on what steps to take next, in order to advance the field. The workshop had three main themes, i.e. (1) techniques to study drug transporter expression and actions in the lungs; (2) drug transporter effects on pulmonary pharmacokinetics (PK) – case studies; and (3) Transporters as drug targets in lung disease.

This report briefly summarises the lectures given at the workshop. In the first part, existing methods and techniques to study the expression and action of pulmonary transporters will be discussed, ranging from targeted proteomics to cell-based in vitro systems to complex ex vivo models. In the second part, case studies will highlight the impact of specific transporters on the distribution of pulmonary administered drugs and in the final section, the evidence on drug transporter contribution to lung disease onset and/or progression will be summarised.
Techniques to study drug transporter expression and actions in the lungs

Characterisation of lung transporters in lung tissues and primary cultured and immortalised lung cells based on quantitative targeted absolute proteomics

Membrane permeability is a key factor in drug absorption, distribution, elimination and efficacy, therefore, knowledge of function, expression and localisation of membrane transporter proteins is important for rational drug discovery and development. A highly selective, sensitive and simultaneous protein quantification method has been developed on the basis of separation and identification of protein digests by liquid chromatography–linked tandem mass spectrometry (LC-MS/MS) with selective reaction monitoring SRM mode. This protein quantification method has been applied for several studies, e.g. the analysis of transporter protein expression difference in organs, animal species and disease models, validation of in vitro models, validation of humanised animal models, prediction of in vivo drug absorption and distribution.

The lung is a very important organ for local drug targeting and systemic delivery. QTAP studies have revealed transporter protein expression in human lung tissues, primary cultured cells and immortalised cell lines. Nineteen transporters (i.e. MDR1, MRP1, MRP3, MRP4, MRP5, MRP6, MRP8, BCRP, OCT1, OCT2, OCTN1, OAT2, OAT3, OAT4, PEPT2, OATP1A2, OATP1B3, OATP2B1 and PGT/OATP2A1) in human lung tissue has been confirmed by QTAP LC-MS/MS analysis. The most abundantly expressed protein was OCTN1. High expression of MRP1, BCRP and PEPT2 protein was also revealed. Interestingly, MRP8 protein expression in female lung was 8-fold higher than that in male specimens, demonstrating a significant gender difference of transporter protein expression.
When commercially available human pulmonary epithelial cells (i.e. tracheal (HTEpiCs), bronchial (NHBEs) and alveolar (HPAEpiCs)) in primary culture were studied, 9 transporters (i.e. MRP1, MRP4, MRP5, MRP6, OCT1, OCT2, OCTN1, OATP1B3 and OATP2B1), 14 transporters (i.e. MRP1, MRP2, MRP3, MRP4, MRP5, MRP6, BCRP, OCT1, OCT2, OCTN1, OAT3, PEPT2, OATP1B3 and OATP2B1) and 8 transporters (i.e. MDR1, MRP1, MRP4, MRP5, MRP6, OCT2, OCTN1 and OATP2B1) were found in detectable quantities in HTEpiCs, NHBEs and HPAEpiCs, respectively. OATP2B1 was detected in all cell types and therefore, might have important physiological roles and could be a useful target transporter for pulmonary drug delivery. MRP1 expressed abundantly in bronchi and alveoli, exhibited an 18-fold maximal inter-individual difference in the bronchial region among 5 donors. Inter-individual differences in apparent efflux activities evaluated by the steady state cell-to-medium ratio of carboxy-dichlorofluorescein (CDF), a model substrate of MRPs in HTEpiCs, NHBEs and HPAEpiCs correlated well with MRP1 protein expression levels in the respective cells examined. OCTN1 expression in primary cultured cells of all three different regions was similar to that of lung tissue. The maximum uptake rate of the organic cation, 4-(4-(dimethylamino) styryl)-N-methylpyridinium iodide (ASP⁺) into HTEpiCs, NHBEs and HPAEpiCs correlated well with OCTN1 transporter protein levels in the plasma membrane fraction of cells from 5 different donors.

QTAP studies were also been performed for 5 commonly used respiratory epithelial cell lines. Interestingly, OCTN1 protein expression in NCI-H441 was shown to be most closely resembling that in primary cells. Similarities and differences of transporter protein expression were shown between the immortalised cell lines and the primary cultured cells, showing limitations of the use of immortalised cell lines. In conclusion, quantitative targeted absolute proteomics is a useful tool to characterise drug transporter protein expression in pulmonary epithelial cells.
expression in lung tissues and to compare primary cultured cells and immortalised cell lines in the context of inhalation biopharmaceutics.

Cell culture models of the air-blood barrier

Cell culture models are a relatively quick and simple means to study mechanisms of drug disposition at the molecular level. Free of the limitations of complex organ systems or indeed living subjects, uptake, transport, metabolism and toxicity can hence be studied in vitro. On the other hand, these models have obvious shortcomings regarding, for example their lack of clearance mechanisms or reduction to mostly a singular cell type, which needs to be considered when interpreting data generated in in vitro assays.

A number of questions need to be addressed when deciding which in vitro model to use:

- Should the model be of human or animal origin? Animal-derived (primary) cells are easier to obtain, but due to species differences they should mainly be used to support in vivo or ex vivo data generated in the same species.

- Should freshly isolated cells in primary culture be used or a continuously growing cell line? Primary cells have arguably the closest resemblance to the in vivo situation, but they are associated with considerably higher cost and effort and eventually will dedifferentiate. Continuously growing cell line, either of cancerous origin or immortalised are generally easier to obtain and can be kept in culture for several passage numbers, but they might differ significantly from their original cell types.

- Also important is the choice of culture conditions. Can the cells be grown at an air-liquid interface or do they require submersed culture conditions? Which medium
and medium supplements should be used and what type of extracellular matrix? For how long can the cells be kept in culture? What is the impact of oxygen pressure? In any case, cell lines that have not been used in a biopharmaceutical context require a thorough characterisation.

The ideal in vitro model would have a cellular phenotype similar to the cell in situ, which in the case of respiratory epithelium, implies the ability to grow to confluent, polarised cell layer(s), a mixed population of cell types, functional cilia (trachea/bronchi/bronchioles), mucus secretion (trachea/bronchi/bronchioles) and/or surfactant production (bronchioles/alveoli) and the expression of drug transporters and metabolic enzymes at the same level and activity as the corresponding barrier. Many of the widely used cancer-derived cell lines, i.e. Calu-3, A549, NCI-H441 and NCI-H292 have significant shortcomings in many of the above mentioned aspects. Similarly, the first generation of simian virus (SV)40 large T antigen-immortalised cell lines, e.g. 16HBE14o- and BEAS-2B often present phenotypes different from the original cell type. More recently generated immortalised cell lines such as NuLi-1, UNCN1T - 3T, VA10, BCI-NS1.1 and hAEVi appear to better resemble the native cells, but most of them have not yet been sufficiently characterised in term of biopharmaceutical applications.\textsuperscript{13, 106-109}

In vitro models of lung epithelium have been extensively used for uptake and transport studies. P-glycoprotein and organic cation transporters are probably the most studied transporters, but also MRPs, peptide transporters and several others have been investigated.\textsuperscript{14,15} Absorption across cell monolayers has been compared to drugs’ physicochemical parameters (e.g. log $P$, polar surface area), to other cell model of lung origin or from other organs (e.g. Caco-2), and with absorption kinetics in isolated lungs or experimental rodent models.\textsuperscript{16-18} The results obtained, however, were frequently
contradictory, which points to a certain heterogeneity in culture conditions, study protocols and marker selection.

Some of the open questions remaining are: do we need organotypic cell culture models? The changing cellular phenotype along the respiratory tree makes it plausible to have different models available representing the large airways, small airways and alveoli, respectively, but are different models for different lung sections really required? Do complex co-culture models offer benefits over mono-cultures? Is the predictive power of the currently available models sufficient to allow IVIVC? Do we need a “Caco-2-like” gold standard for the lungs? Do transport study conditions matter?

**Precision-cut lung slices for profiling of inhaled compounds**

Development of locally acting inhaled drugs for the treatment of respiratory disease relies on the optimisation of compound and/or formulation properties to achieve retention in the lung that provides a sufficient level and duration of local exposure.\(^{19}\) Whilst most small drug molecules are rapidly absorbed across the pulmonary epithelium, molecular properties such as lipophilicity and basicity which are normally associated with increase tissue binding,\(^{20}\) have been found to be also associated with enhanced lung retention.\(^{19}\) This observation triggered the investigation of how the extent of lung tissue binding, determined in precision-cut lung slices, relates to lung retention and the effect duration of inhaled bronchodilators.

Using a framework originally developed for studying brain tissue\(^{21}\) lung tissue binding described as the unbound drug volume of distribution in the lung (\(V_{u,\text{lung}}\)) was found to be lower for salbutamol (2.2 ml/g) than for longer acting \(\beta_2\)-adrenergic bronchodilators including the AZD3199 (2970 ml/g), suggesting that binding is a drug property that may be
relevant to profile and modulate in the optimisation of inhaled drugs. Further insight to the mechanisms of lung tissue binding was provided by modulation of lysosomal pH using monensin: a substantial proportion of basic bronchodilators was found to reside in these compartments and to slow down the rate of drug release from tissue as studied in the slices.\textsuperscript{22}

Moreover it was shown that ipratropium, a quaternary amine and an anti-muscarinic bronchodilator, had an accumulation in lung slices that was 8-fold higher than what would be expected from lung tissue binding determined in homogenate of lung tissue. This points to the existence of a carrier mechanism in its cellular accumulation. Interestingly, ipratropium is a substrate for OCT and OCTN transporters\textsuperscript{23} and the intracellular accumulation of the prototypic OCT substrate MPP\textsuperscript{+} was 100-fold higher than binding in lung homogenate.\textsuperscript{24} Whilst both beta-agonist\textsuperscript{25} and beta-antagonists\textsuperscript{26} are also substrates for OCT transporter the contribution to cellular accumulation is likely lower.

Besides providing an integrated experimental system to predict lung retention for certain classes of drugs, the specific information of lung tissue binding obtained from slices is can be integrated with other measured drug or formulation properties through physiologically based pharmacokinetic (PBPK) modelling by which the complex interplay between drug properties and lung physiology can be explored and understood. PBPK modelling also bears promise for scaling inhalation pharmacokinetics from animals to man.\textsuperscript{27,28}

\textbf{Isolated and perfused lung models}
Absorptive clearance of drug from the lungs is important for the efficacy and safety of inhaled medicines.\textsuperscript{29,30} Transporters have the potential to significantly influence drug absorption, but to date most of the experimental evidence for the presence and impact of drug transporters in the lungs comes from immunohistochemical identification of transporters in lung tissue and \textit{in vitro} studies using respiratory epithelial cell cultures, respectively\textsuperscript{14,15,31,32} Such techniques cannot show the influence of transporters on pulmonary absorption – for this, air to blood solute transfer in intact lungs must be measured.

Isolated perfused lungs offer unique opportunities to investigate the effect of drug transporters on lung permeability.\textsuperscript{33} In this technique, the lungs are isolated from the systemic circulation, perfused via the pulmonary circulation and ventilated via the trachea. Using isolated perfused lungs, it is possible to deliver precise concentrations of transporter substrates/inhibitors, measure bi-directional drug transfer (from lung to perfusate and perfusate to lung), pre-administer transporter inhibitors and use inhibitors in concentrations and combinations that are not possible \textit{in vivo}. Whilst rat lungs are the most commonly used, it is possible to use the lungs of genetic knockout mice\textsuperscript{34} and lobes of human lungs.\textsuperscript{35}

Intrinsic and formulation-driven pharmacokinetics have been investigated following pulmonary administration of drugs to isolated perfused lungs. The rate and extent of drug transfer from airway to perfusate has been used to establish relationships with molecular properties,\textsuperscript{16,36} permeability in epithelial cell models\textsuperscript{16,18} and drug absorption \textit{in vivo}.\textsuperscript{16} The effectiveness of a variety of absorption-modifying drug delivery strategies on absorptive clearance from the lungs has been investigated, including polymer microparticles.\textsuperscript{37}
liposomes, sequence-specific phage display-derived peptide conjugated dendrimers, and drug-ester polymer conjugates.

Isolated perfused lungs have been used less extensively to study the impact of drug transporters on absorptive clearance. Airway to perfusate transfer of losartan, a P-glycoprotein substrate, was not retarded in absorptive permeability in isolated rat lungs. This finding was consistent with rapid the pulmonary absorption of losartan in vivo; similarly, no effect on the absorption of another P-gp substrate, digoxin, has been reported in MDR1a-deficient mice. However, subsequent detailed investigations have demonstrated convincingly using isolated perfused lungs with inhibitors and genetic knockout that the impact of P-gp on absorptive pulmonary permeability is substrate specific (see below). The OCT/OCTN transporter substrates ipratropium and L-carnitine have been shown to transfer into the pulmonary circulation of isolated rat lungs by passive processes rather than active uptake. However, the effect of methacholine on transport of β-agonists through competition for organic cation/carnitine transporters has been demonstrated in human lungs and linked to lung mechanics. In other studies, active transport in isolated rat lungs has also been demonstrated for IgG transported by neonatal constant region fragment receptor and the absorptive permeability transport of polyhydroxyethylaspartamide. To fully exploit the potential of isolated perfused lungs to study the influence of drug transporters, it would be useful to establish best practice in performing such studies, e.g. demonstration of saturation / concentration-dependency, use of inhibitors, controls and genetic knockouts, confirmation of findings using complimentary techniques and the demonstration that drug kinetics link to effect on lung mechanics.
A novel Quantitative Structure-Activity Relationship (QSAR) model to accurately predict pulmonary absorption

A literature analysis of the physicochemical properties of respiratory drugs concluded that inhaled respiratory drugs have a higher hydrogen bonding capacity, polar surface area and molecular weight and lower lipophilicity compared to oral respiratory drugs. The authors also concluded that inhaled drugs with different pharmacological action occupy distinct property space which may limit the application of this information to the design of compounds for novel targets of most diverse respiratory disease.

To facilitate inhaled drug design for more novel respiratory targets a novel in silico model was constructed using the largest, diverse and relevant pulmonary absorption data set available to date, combining both marketed inhaled drugs and novel inhaled compounds. A pulmonary absorption dataset generated using the isolated and perfused rat lung (IPRL) ex vivo model, for 82 drug discovery compounds and 17 marketed drugs, was used to build a novel Quantitative Structure-Activity Relationship (QSAR) model based on calculated physicochemical properties. The model predicted the percentage of the solubilised fraction of the dose, crossing the lungs into the perfusate over a 20 minute timeframe, following intra-tracheal instillation as an aqueous solution/suspension. A further 9 compounds were used to test the model’s predictive capability, with the QSAR model performing well on this “test set” with a predicted versus observed correlation of $R^2 = 0.85$, and >65% of compounds correctly categorised. Calculated descriptors associated with permeability and hydrophobicity positively correlated with pulmonary absorption, whereas those associated with charge, ionisation and size negatively correlated. These findings were in keeping with literature describing physicochemical drivers of pulmonary absorption for a variety of
compounds. The novel QSAR model described can replace routine generation of IPRL model data for ranking and classifying compounds prior to synthesis therefore facilitating compound design through improved prediction of pulmonary absorption. It will also provide scientists working in the field of inhaled drug discovery with a deeper understanding of the physicochemical drivers of pulmonary absorption based on a relevant respiratory compound dataset.

Computer based mechanistic models as a means to understand the impact epithelial permeability/transport on local and systemic drug exposure after inhalation

Effective drug design requires a means to predict the impact of changes to product, material and molecular properties on the clinical performance of the medicine. Lately, computer based mechanistic models have shown promise. For instance, it was demonstrated that the clinically observed variation in rate and extent of absorption into the systemic circulation of a poorly soluble inhaled drug could be rather accurately predicted based on deposition pattern, dissolution rate and molecular physiochemical properties for a range of formulations and devices. Using the same mechanistic model (GastroPlus™ 9.0, Simulations Plus Inc., Lancaster, CA), extent and rate of systemic absorption was simulated as a function of: Deposition region; Solubility and Permeability (Figure 1).

Results show that the extent and rate of absorption follow a pattern with respect to the impact of solubility and permeability which is akin to that of an oral drug. A rough comparison with the oral biopharmaceutical classification system revealed that:
• BCS1 like drugs (high permeability and high solubility) are generally rapidly and completely absorbed from peripheral lung regions. It is likely that these drugs would show limited lung targeting.

• BCS4 like drugs (low permeability and low solubility) are generally expected to be very poorly absorbed from conducting airways regions as result of mucociliary clearance. It is likely that these drugs may demonstrate a very poor effect in conducting airway regions.

• BCS2/3 like drugs show some promise in terms of having some conducting airway bioavailability and a delayed absorption rate. This is likely the classes of compounds where we would expect to find most successful inhaled drugs. Nevertheless, the predicted low uptake (F) in large (0.1 – 0.4%) and small airways (3.4 – 11.6%) would put emphasis on highly potent drugs, especially given the low doses of standard inhalation formulations (cf. Figure 1).

Overall, simulation results indicated that the clinical property of an inhaled medicine would (as could be expected) be very dependent on deposition pattern, but also on the interplay between solubility, permeability (and obviously target affinity).

The heterogeneity of the lung (ranging from large, low permeable, mucociliary cleared conducting airways to the large-surface, highly permeable, highly perfused, alveolar gas exchange region), could be expected to generate regional differences in active drug concentration time profiles. For instance, selective local targeting of fluticasone propionate to conducting airway tissue was suggested to explain its observed local clinical efficacy in absence of total lung targeting (as measured by receptor occupancy).
Although computer-based mechanistic modelling thus show significant promise in bringing about a better understanding of local drug tissue levels in relation to drug and product properties, access to good quality input parameters is vital. Today, airway permeability and the impact (if any) of active transport in airways is among the least understood of these parameters. Especially, in conducting airways, a region of significant clinical importance, airway permeability could govern both extent and rate of absorption and should therefore be further investigated.

Drug transporter effects on pulmonary PK – case studies

P-glycoprotein transport in the lungs

P-glycoprotein (P-gp), encoded by the MDR1 gene in humans and the mdr1a and mdr1b genes in rodents, is amongst the most widely studied pharmaceutically relevant transport. P-gp substrates cover a broad range of drug classes and physicochemical properties although they tend to be lipophilic or amphipathic.\(^5\)

Evidence for P-gp expression within whole lung includes both mRNA and protein data in both humans and rodents\(^5\)\(^2\)\(^-\)\(^5\(^8\)\) (reviewed in\(^1\(^4\),\(^1\(^5\),\(^3\(^1\),\(^5\(^9\)), although indications are that the lung displays lower levels of P-gp than in other tissues normally associated with pharmaceutical barrier functions. However, it is the spatial microanatomic localisation of P-gp to lung epithelium that needs to be considered: P-gp expression is recognised at the luminal surface of bronchial/bronchiolar epithelium\(^5\(^4\)-\(^5\(^9\)\) and within alveolar epithelium.\(^5\(^4\),\(^5\(^5\)\) Nevertheless, the impact of P-gp upon pulmonary PK of inhaled drugs is poorly understood, and requires experiments performed in the intact lung where anatomically accurate tissue architecture is
maintained and appropriate parallel processes of clearance from the airways are preserved, including studies performed in isolated perfused organ models.

Using an IPRL model Kuhlmann et al. in 2003 reported P-gp to limit the transport of a P-gp substrate, idarubicin, from the pulmonary circulation into lung tissue, indicative of P-gp expression within pulmonary capillary endothelial cells. In 2004, Roerig et al. using a rabbit model made a similar report for rhodamine 6G. However, these findings have not been corroborated.

Functional studies that directly or indirectly address airway to blood absorption and the impact of P-gp include: Tronde et al. where as part of a broader study of pulmonary absorption and drug structural properties the extent of absorption for the P-gp substrate losartan was reported to be >90% from the airways. In 2008, Manford et al. reported the pulmonary absorption of the P-gp substrate digoxin to remain unchanged in CF-1 mice, which display spontaneous mdr1a knockout, although retaining mdr1b expression. In an IPRL model the same group reported that co-administration into the airways of a P-gp inhibitor had no effect upon the pulmonary absorption profile of digoxin. Contrary to this, a similar study in the IPRL showed a significant increase in the absorption of the P-gp substrate rhodamine 123 when co-dosed with the P-gp inhibitor, GF120918.

Subsequently, a study was undertaken in both IPRL and isolated perfused mouse (IPML) lung models that began to explore the above divergent findings. Using a comparatively small panel of five P-gp substrates the impact of P-gp upon airway instilled P-gp substrates (including the archetype digoxin and rhodamine 123 molecules) resulted in disparate outcomes with some substrates affected by P-gp and others not. From here the same group used genetic knockout P-gp mice in an IPML model and examining a much broader panel.
(i.e. 18 molecules) of P-gp substrates instilled into the airways (Price et al. unpublished observation). The outcome for this larger panel again showed divergent outcomes between the substrates separating into two distinct sub-populations; those whose pulmonary absorption was affected by P-gp and those unaffected. These polarised groupings could be entirely distinguished by their differing computed physicochemical properties and not by more global biological properties such as P-gp binding affinity ($K_m$) or turnover ($V_{\text{max}}$). In general the more polar the P-gp substrate the less its pulmonary absorption was impacted by P-gp. To put this in context, the same panel was tested in intestinal absorption studies in the P-gp knockout and control mice. Here no distinct sub-populations could be identified. The only study on P-gp effect on pulmonary absorption in man found that oral verapamil increased the area under the curve (AUC) of inhaled umeclidinium bromide and vilanterol by approximately 40%. In that study, however, the concentrations of inhalants were a multiple of the approved clinical dose and the timing between administration of the oral inhibitor and the begin of the inhalation manoeuvre was suboptimal.

In summary, work is beginning to identify specific physicochemical properties for P-gp substrates that predict if their absorption from the lung may be affected by P-gp; these same physicochemical signatures do not predict the effect of P-gp upon intestinal absorption.

Interaction of organic cation transporters with bronchodilators in vitro, ex vivo and in vivo

Organic cation transporters (i.e. OCT1-3 and OCTN1, 2) belong to the SLC22 gene-family. Organic cation transporters (i.e. OCT1-3 and OCTN1, 2) belong to the SLC22 gene-family. The majority of inhaled drugs, e.g. bronchodilative $\beta_2$-adrenergic agonists and anti-muscarinics are either permanent cations or bases, whilst several inhaled corticosteroids
have been reported to be OCT inhibitors (Table 1). Therefore, this family of transporters has received considerable attention in the past 10 to 15 years. The vast majority of data have been generated in cell-based *in vitro* models, often reporting conflicting findings. This might be explained by different culture conditions of primary cells and cell lines which can result in changes in transporter expression and activity. Organic cation accumulation and absorption in lung tissues, however, was also studied in lung slices and perfused organ models, respectively. An involvement of OCT/N transporters in the pulmonary absorption of salbutamol was proposed already in 2005, and although many publications were published demonstrating OCT/N expression and activity in lung tissues and cell cultures, the molecular identity of the transporters responsible was not clarified until recently, when functional studies using OCT over-expressing expression systems showed that OCT1 and OCT3 exhibit high affinities for β<sub>2</sub>-adrenergic agonists. Direct evidence, using either radiolabelled probes, RNAi or overexpression studies demonstrating evidence on the contribution of OCTN1, 2 in β<sub>2</sub>-adrenergic agonists transport is still outstanding. OCTN contribution to the uptake of ipratropium, on the other hand, has been shown *in vitro* and *in vivo*, but the role of the transporters in pulmonary transport and lung PK of anticholinergics is still controversially discussed.

**Functional expression of PEPT2 and its regulation in alveolar epithelial cells**

The di- and tri-peptide transporters, PEPT1 (SLC15A1) and PEPT2 (SLC15A2) transport various peptidomimetic drugs such as β-lactam antibiotics and antivirals, and have an important role, for example in the absorption of these drugs from the intestine. PEPTs are
secondary active transporters, and transport their substrates coupled with an electrochemical proton gradient.⁷²

PEPT2 is functionally expressed in alveolar epithelial type 2 cells, but not in type 1 cells.⁷³ However, the widely used cell lines with alveolar epithelial type 2-like phenotype such as A549 (a cell line derived from human lung adenocarcinoma) and RLE-6TN (a cell line derived from rat normal lung) do not have substantial PEPT2 activity. The human distal lung epithelial cell line, NCI-H441 has recently been reported to have PEPT2 activity.⁷⁴ In NCI-H441 cells, PEPT2 protein is expressed on the apical membrane and facilitates the uptake of PEPT2 substrates into the cells. At this moment, the pharmacological role of alveolar PEPT2 in the pulmonary absorption of peptidomimetic drugs after inhalation is not entirely clear. Physiologically, PEPT2 might be involved in the innate immune response via a nucleotide-binding oligomerisation domain 1 (NOD1)-dependent mechanism,⁷⁵ as it has been shown that the bacterial dipeptide, γ-D-glutamyl-meso-diaminopimelic acid (γ-iE-DAP), an initiator of this response, can be taken up by PEPT2. It is very interesting and important to further clarify the pharmacological and physiological roles of PEPT2 in the human lung.

Implications of the carrier-mediated transport of nicotine in lung and other tissues

Although nicotine is rapidly absorbed from the lung and distributed to the brain after tobacco smoking,⁷⁶ our knowledge of the transport mechanism by which nicotine crosses the alveolar epithelial barrier and blood-brain barrier is incomplete. Nicotine uptake by A549 human carcinoma-derived cells with an alveolar epithelial type 2 cell-like phenotype was found to be time-, temperature-, and concentration-dependent with a Michalis-Menten constant of 50 µM, suggesting that a carrier-mediated process is involved in nicotine
transport in alveolar epithelial cells. Nicotine absorption was reduced by hydrophobic cationic drugs such as verapamil and pyrilamine, whereas typical substrates and inhibitors of organic cation transporters did not show inhibitory effect. The transport mechanism of nicotine in alveolar epithelial cells shows great similarity to that in a brain capillary endothelial cell line in vitro. This evidence suggests that the newly identified organic cation transport system is involved in nicotine transport process in lung and the blood-brain barrier. Once taken up by alveolar epithelial and brain endothelial cells, nicotine could further be efflux to the blood from the lung and to the brain from the blood, respectively. Currently, however, little is known regarding the mechanisms underlying the efflux of nicotine at the basolateral membrane of alveolar epithelial and brain endothelial cells. Nevertheless, this transport might offer the opportunity of delivering cationic drugs to the brain after inhalation.

Pulmonary transporters in the drug disposition of antibiotics

When tissue distribution is only governed by passive diffusion, unbound AUC in plasma and tissue extra-cellular fluid (ECF) should be identical, whereas in the presence of active efflux, unbound AUC should be lower in tissue ECF than in plasma. Drug concentrations can be measured within lung epithelial lining fluid (ELF) after broncho-alveolar lavage (BAL) from laboratory animals or humans, and correction for dilution can obtained by measuring urea in plasma and BAL. Because albumin concentrations in the alveolar lining fluid are extremely low compared with those in plasma under normal condition (<10% of plasma), one can assume that estimated ELF concentrations correspond to unbound drug concentrations.
A series of experiments has recently been initiated using well controlled experimental conditions, in order to develop a biopharmaceutical classification of nebulised antimicrobial agents, based on their water solubility and membrane permeability. Healthy rats were used for these experiments. Antibiotics were administered intravenously or nebulised using a Penn-Century MicroSprayer®. This system allows most of the dose to reach the bronchial alveoli where the drug can be systemically absorbed. Simultaneous BAL and plasma sampling was conducted at various time points post-dosing for assessment of drug concentrations. The route of administration had a major effect on lung PK for antibiotics presenting low membrane permeability (and therefore low and even virtually negligible oral bioavailability allowing only parenteral administration in clinical practice), such as colistin, tobramycin or aztreonam, with much higher ELF concentrations after nebulisation when compared to intravenous administration at the same dose, and much higher ELF concentrations than unbound plasma concentrations after nebulisation. By contrast, the route of administration had no detectable effect on ELF and unbound plasma concentrations for antibiotics with relatively high membrane permeability (and therefore high oral bioavailability allowing oral administration in patients), such as ciprofloxacin or moxifloxacin. Yet the profound differences observed between compounds were related to differences in membrane permeability, essentially controlled by passive diffusion and irrespective of active transport phenomena.

However, the higher ELF than unbound plasma concentrations observed with moxifloxacin independently of the route of administration suggested or at least were consistent with an active efflux transport (Figure 2). Moxifloxacin is highly permeable and therefore, its distribution equilibrium occurs rapidly after both intravenous administration and nebulisation. Nonetheless, moxifloxacin is also a P-glycoprotein substrate, which could
explain why ELF concentrations were higher than unbound plasma concentrations. Although unlikely, one cannot totally exclude that ELF concentrations may have been over-estimated after moxifloxacin present within cells (e.g. macrophages) was released to ELF during BAL sampling. In fact, such differences between ELF and unbound plasma concentrations were not observed with ciprofloxacin, also a known P-gp substrate. Therefore, the in vivo effect of P-gp on moxifloxacin lung PK should be further confirmed using appropriate knock-out animals. Alternatively, interaction studies with potent, specific and non-toxic competing P-gp substrates or inhibitors could be conducted in whole animals or/and using an isolated and perfused lung model. For low-permeability drugs it will take time to reach equilibrium distribution and therefore, the effect of an efflux transport system on the lung PK would probably be observable after multiple dosing at steady-state, but not after single dose administration, which was confirmed by PK studies.

**Transporters as drug targets**

Organic cation transporter OCTN1 as possible target for lung pathology

The *SLC22A4* gene has been identified to be associated with several diseases such as rheumatoid arthritis,\textsuperscript{85} Crohn’s disease,\textsuperscript{86} autoimmune thyroid disease\textsuperscript{87} and recessive non-syndromic hearing loss DFNB60 in humans.\textsuperscript{88} This implies that the OCTN1 transporter could play a role in onset and/or deterioration of these diseases although little information is available on the molecular mechanisms. Since OCTN1 was originally identified as a xenobiotic transporter, which accepts various types of organic cations as substrates *in vitro*, identification of its substrate(s) *in vivo* may help understanding of how this transporter is associated with those diseases. Thus *octn1* gene knockout (*octn1*\textsuperscript{-/-}) mice were generated
and metabolome analysis of blood and several organs in both wild-type and octn1−/− mice was carried out, leading to the identification of the food-derived antioxidant, ergothioneine (ERGO) as the physiological substrate of OCTN1. This finding was in agreement with metabolome analysis using SLC22A4 gene transfected cell lines, which originally identified ERGO as OCTN1 substrate. ERGO is furthermore demonstrated to be possible biomarker substance in both rheumatoid arthritis and Crohn’s disease.

Since oxidative stress is associated with various types of inflammatory diseases, speculating about a protective role for OCTN1 by transporting ERGO into cells to reduce oxidative stress is warranted. This protective role of OCTN1 was recently studied in tobacco smoke-induced chronic obstructive pulmonary disease (COPD). Exposure to tobacco smoke leads to oxidative stress, which contributes to alveolar wall destruction, mucus hyper secretion, inflammation and defective tissue repair. Semi-quantitative PCR and immunoblot revealed elevated expression levels of catalase, thioredoxin and sulfiredoxin-1 following treatment with ERGO in NCI-H441 cells. Moreover, lower levels of oxidative stress were observed in cells, which were cultured in the presence of ERGO prior to the exposure to cigarette smoke extract. When exposed to room air, octn1−/− mice showed little differences compared to wild-type mice. However, numbers of total cells and PNMs in BAL fluid as well as increased alveolar damage and increased inflammatory markers were observed in octn1−/− mice compared to wild-type mice, when exposed to second-hand smoke. These data suggest that ERGO can protect lung epithelial cells from oxidative damage and consequently, variants of OCTN1 might play a role in the pathogenesis of tobacco smoke-induced COPD by regulating ERGO transport.
Pathophysiological role of prostaglandin transporter OATP2A1/SLCO2A1 in pulmonary fibrosis

Prostaglandin (PG) E₂ is a bioactive lipid produced from arachidonic acid via the cyclooxygenase (COX)-PGE synthase (PGES) pathway. The prostaglandin transporter, OATP2A1 (aka PGT) encoded by the \textit{SLCO2A1} gene has been characterised as an importer with high affinity to PGE₂, PGF₂α and PGD₂ at plasma membranes.\textsuperscript{94,95} Recent genome-wide association studies indicate a link of loss-of-function mutations in \textit{SLCO2A1} with primary hypertrophic osteoarthropathy\textsuperscript{96} and chronic non-specific multiple ulcers of the small intestine.\textsuperscript{97} Since PGE₂ is anti-fibrotic to lung stromal cells\textsuperscript{98} and OATP2A1 is expressed functionally in mouse lungs\textsuperscript{99} and the human bronchial epithelial BEAS-2B cells,\textsuperscript{100} the effect of the absence of \textit{Slco2a1} on pulmonary fibrosis in intra-tracheally (i.t.) bleomycin-injected mice was studies.\textsuperscript{101} Immunohistochemistry showed that abundant expression of Oatp2a1 in mouse type 1 alveolar epithelial cells (AT1), and PGE₂ uptake was almost diminished in \textit{Slco2a1}⁻/⁻ mice-derived AT1-like cells. Bleomycin-induced interstitial pneumonia and fibrosis became more severe in \textit{Slco2a1}⁻/⁻ mice, manifesting greater airway infiltration of inflammatory cells, collagen deposition and TGF-β1 signalling-related gene expressions (e.g. \textit{Tgf-b1} and \textit{Pai-1}). Two weeks after the i.t. injection, Western blot analysis demonstrated a significant activation of protein kinase C (PKC)-δ in the lungs of \textit{Slco2a1}⁻/⁻ mice, which contributes to an excessive production of extracellular matrix. Moreover, PGE₂ levels approximately 5-fold elevated significantly in BAL fluid of bleomycin-injected \textit{Slco2a1}⁻/⁻ mice, compared to that of wild type (WT) counterparts, although no other eicosanoids were found to increase in the BAL fluid by means of eicosanoid targeting metabolomics analysis. On the other hand, PGE₂ concentration in lung homogenates tended to decrease in \textit{Slco2a1}⁻/⁻ mice. Accordingly, altered PGE₂ disposition in the lung of \textit{Slco2a1}⁻/⁻ mice may contribute to
aggravation of pulmonary fibrosis induced by bleomycin. It is hypothesised that PGE\(_2\) released into alveolar lumen from epithelium and inflammatory cells infiltrated airway could transverse across AT1 cells into the lung interstitium via luminal OATP2A1, and then, inhibits fibroblast activation. This hypothesis is also supported that fact that PKC-δ was negatively regulated by c-AMP produced by PGE\(_2\) signals in human lung fibroblasts.\(^{102,103}\) Moreover, it was recently found that intracellular OATP2A1 mediates exocytosis of PGE\(_2\) from murine macrophages,\(^{104}\) therefore, PGE\(_2\) autocrine signal may be altered in infiltrated monocytes and involved in severe inflammation. Revealing the precise role of OATP2A1 in tissue remodelling, which has been unappreciated to date, may provide a new rationale for mechanism of action of PGE\(_2\) and possibly for pulmonary fibrosis.

**Summary and conclusions**

Lung transporter research is conducted in a small number of academic and industry laboratories with wider interest limited pending the first case studies to illustrate that drug-transporter interactions in the lungs have clinical impact. Although some studies have shown effects of transporters on drug absorption from the lungs, there are no scientific reports to the authors' knowledge that provide evidence of a significant impact on target engagement or drug activity in the lungs. However, the potential impact that transporters may have in determining local free drug concentrations in target lung compartments (and thus drug action in the lungs) may be missed by insensitive measures such as net lungs-to-blood absorptive clearance. The potential for inhaled medicines to affect normal physiological processes, i.e. those mediated via the endogenous substrates of transporters,
provides a further reason to understand better the way in which inhaled drugs interact with transporters during their residence in the lungs.

A barrier to progress in studying drug transporters in the lungs is that techniques required for evaluating impacts on local drug disposition are not routinely available or relatively recently developed. This includes methods to deliver appropriate doses and distributions of aerosolised drug accurately into the lungs of small animals or isolated perfused lungs, methods to study receptor occupancy as a surrogate for drug action following administration of drugs to the lungs and mechanistic modelling approaches, which can discern the impact of transporter kinetics in the context of competing pathways for drug clearance. Such models can be used to generate hypotheses for experimental testing and develop deeper understanding of inhaled drug biopharmaceutics. Priorities for further research in the field have been laid out previously by Gumbleton and colleagues in 2011 and it is interesting to revisit these to see what progress has been made (Table 2).  

The advantages and limitations of the different systems in which lung transporters are studied should also be considered (Table 3), so that these can be used in complementary study designs to investigate transporter interactions using triangulation to confirm hypotheses and observations. Cell cultures provide convenient systems in which transporters are expressed and can be characterised for their substrate specificity, drug-interactions and kinetics. Ex vivo lungs enable drug transport to be studied in a model that possesses the architecture of the lungs and can be combined with delivery by inhalation and measurement of lung function. For example, the IPL has been used to examine the link between PK and lung mechanics. In vivo studies permit less precise control of experimental conditions, but are the ultimate proof of impact of transporter actions.
In conclusion, it is well established that transporters for which licensed inhaled molecules are substrates are present in the lungs. New drug candidates for treating respiratory disease may include different chemical classes, with different transporter affinities. Furthermore, the molecularly diverse drugs that may be delivered via the lungs for systemic action may also bring different transporters into play. The physiological role for these transporters may provide clues regarding their likely impact on local disposition of drugs in the lungs. The influence of disease on these transporters may also be important. For drugs that have targets in the lungs, the effect of transporters on inhaled drug biopharmaceutics is not adequately investigated if only systemic exposure is measured and carefully designed studies are needed to measure effects in the lungs themselves.
ACKNOWLEDGEMENTS

This work has been financially supported by an International Strategic Collaboration Award from Science Foundation Ireland and co-sponsored by the Japanese Society for the Study of Xenobiotics (JSSX). The authors would like to thank Joe Moore (NUI Galway) for logistical support and acknowledge the contribution of the COST Actions BM1201 and MP1404.
REFERENCES


Figure Legends

**Figure 1.** Impact of deposition, solubility and permeability on extent and rate of systemic absorption.

**Figure 2.** Concentration-time profiles of moxifloxacin following i.v. administration and administration of the nebulised form in plasma (red line, closed symbols) and in ELF (blue line, open symbols), predicted from simultaneous PK modelling of plasma and ELF data. Symbols represent means ± SD concentrations measured in plasma and ELF. Taken from 79.
Table 1. List of FDA-approved drugs for inhalation with reported organic cation transporter interactions (adapted from \textsuperscript{15,110})

<table>
<thead>
<tr>
<th>Compound</th>
<th>Drug Class</th>
<th>Transporters</th>
</tr>
</thead>
<tbody>
<tr>
<td>Salbutamol</td>
<td>β\textsubscript{2}-Adrenergic agonist</td>
<td>OCT1, OCT3, OCTN1(?), OCTN2(?)</td>
</tr>
<tr>
<td>Beclomethasone dipropionate</td>
<td>Corticosteroid</td>
<td>OCT1, OCT2</td>
</tr>
<tr>
<td>Budesonide</td>
<td>Corticosteroid</td>
<td>OCT1-3</td>
</tr>
<tr>
<td>Ciprofloxacin</td>
<td>Antibiotic</td>
<td>OCT-3, OCTN2*</td>
</tr>
<tr>
<td>Fenoterol</td>
<td>β\textsubscript{2}-Adrenergic agonist</td>
<td>OCT1, OCT2</td>
</tr>
<tr>
<td>Fluticasone propionate</td>
<td>Corticosteroid</td>
<td>OCT2, OCT3</td>
</tr>
<tr>
<td>Formoterol</td>
<td>β\textsubscript{2}-Adrenergic agonist</td>
<td>OCT1, OCT3, OCTN2</td>
</tr>
<tr>
<td>Indacaterol</td>
<td>β\textsubscript{2}-Adrenergic agonist</td>
<td>OCT1, OCT2</td>
</tr>
<tr>
<td>Ipratropium bromide</td>
<td>Anticholinergic</td>
<td>OCT2, OCTN2*</td>
</tr>
<tr>
<td>Levofloxacin</td>
<td>Antibiotic</td>
<td>OCT2*</td>
</tr>
<tr>
<td>Olodaterol</td>
<td>β\textsubscript{2}-Adrenergic agonist</td>
<td>OCT1*</td>
</tr>
<tr>
<td>Pentamidine</td>
<td>Antiprotozoal</td>
<td>OCT1-3*</td>
</tr>
<tr>
<td>Salmeterol xinafoate</td>
<td>β\textsubscript{2}-Adrenergic agonist</td>
<td>OCT1, OCT3</td>
</tr>
<tr>
<td>Terbutaline</td>
<td>β\textsubscript{2}-Adrenergic agonist</td>
<td>Oct1*, Oct2 *</td>
</tr>
<tr>
<td>Tiotropium bromide</td>
<td>Anticholinergic</td>
<td>OCT2, OCTN2*</td>
</tr>
</tbody>
</table>

Bold face indicates drugs which act as inhibitors

*, Interactions were found in non-lung tissues or cells
?, Contradictory information
Table 2. Research priorities identified by Gumbleton et al. 2011.\textsuperscript{14}

<table>
<thead>
<tr>
<th>Research priorities</th>
<th>Examples of progress</th>
</tr>
</thead>
<tbody>
<tr>
<td>Identify transporters in human lungs and other species used in preclinical evaluation of inhaled medicines</td>
<td>Summarised by Nickel et al. 2016\textsuperscript{15} and Gustavsson et al. 2016\textsuperscript{32}</td>
</tr>
<tr>
<td>Map levels and locations of transporter expression within the lungs</td>
<td>Summarised by Nickel et al. 2016\textsuperscript{15} and Gustavsson et al. 2016\textsuperscript{32}</td>
</tr>
<tr>
<td>Demonstrate the impact of transporters on drug retention or disposition in the lungs after inhalation</td>
<td>Data on P-gp effects from IPL and \textit{in vivo} animal work, e.g.\textsuperscript{34,63,71}</td>
</tr>
<tr>
<td>Study the effect of transporters on accumulation of drug in the lungs from the systemic circulation</td>
<td>Forbes has investigated uptake via the polyamine transporter (unpublished data); Paraquat accumulation in lung tissue\textsuperscript{105}</td>
</tr>
<tr>
<td>Do inhaled drugs alter transporter expression or function (thereby affecting normal physiology)</td>
<td>No evidence yet</td>
</tr>
<tr>
<td>Clinical impact of transporters, e.g. drug-drug interactions, effect of disease, inter-individual variability</td>
<td>Methacholine caused decrease of $\beta_2$ agonist absorption in human IPL;\textsuperscript{35} Oral verapamil increased AUC of inhaledumeclidinium and vilanterol in human volunteers\textsuperscript{64}</td>
</tr>
</tbody>
</table>
Table 3. Experimental models for measuring effects of transporters on drug disposition in the lungs

<table>
<thead>
<tr>
<th>Experimental system</th>
<th>Advantages</th>
<th>Limitations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Respiratory cell cultures</td>
<td>• Primary cell cultures and many cell lines available</td>
<td>• Usually only single cell type</td>
</tr>
<tr>
<td></td>
<td>• High capacity, readily available</td>
<td>• Many clearance mechanisms missing</td>
</tr>
<tr>
<td></td>
<td>• Measurement of transport or cell uptake</td>
<td>• Relevance to lung effects unclear?</td>
</tr>
<tr>
<td></td>
<td>• Measurement of metabolism</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Molecular identification of pathways possible</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Isolated perfused lungs</td>
<td>• Human lung lobes can be used</td>
<td>• Species differences unclear</td>
</tr>
<tr>
<td></td>
<td>• Can be linked to lung function measurement</td>
<td>• Access to human lung is limited</td>
</tr>
<tr>
<td></td>
<td>• Can study air to blood and blood to lung transport</td>
<td>• Short study duration</td>
</tr>
<tr>
<td></td>
<td>• Can use inhibitors in high concentrations, controlled concentrations</td>
<td>• Not trivial to set up</td>
</tr>
<tr>
<td></td>
<td>• Use of genetically modified animals possible</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>In vivo experiments</td>
<td>• Lung function can be measured</td>
<td>• Use of inhibitors and concentrations limited</td>
</tr>
<tr>
<td></td>
<td>• Disease models can be used</td>
<td>• Studies in humans are limited</td>
</tr>
<tr>
<td></td>
<td>• Use of genetically modified animals possible</td>
<td></td>
</tr>
<tr>
<td>Deposition (region)</td>
<td>Solubility (µM)</td>
<td>Peff (cm/s)</td>
</tr>
<tr>
<td>--------------------</td>
<td>----------------</td>
<td>------------</td>
</tr>
<tr>
<td>BB</td>
<td>0.1</td>
<td>Hi</td>
</tr>
<tr>
<td>BB</td>
<td>0.1</td>
<td>Lo</td>
</tr>
<tr>
<td>BB</td>
<td>10</td>
<td>Hi</td>
</tr>
<tr>
<td>BB</td>
<td>10</td>
<td>Lo</td>
</tr>
<tr>
<td>BB</td>
<td>1000</td>
<td>Hi</td>
</tr>
<tr>
<td>BB</td>
<td>1000</td>
<td>Lo</td>
</tr>
<tr>
<td>bb</td>
<td>0.1</td>
<td>Hi</td>
</tr>
<tr>
<td>bb</td>
<td>0.1</td>
<td>Lo</td>
</tr>
<tr>
<td>bb</td>
<td>10</td>
<td>Hi</td>
</tr>
<tr>
<td>bb</td>
<td>10</td>
<td>Lo</td>
</tr>
<tr>
<td>bb</td>
<td>1000</td>
<td>Hi</td>
</tr>
<tr>
<td>bb</td>
<td>1000</td>
<td>Lo</td>
</tr>
<tr>
<td>Al</td>
<td>0.1</td>
<td>Hi</td>
</tr>
<tr>
<td>Al</td>
<td>0.1</td>
<td>Lo</td>
</tr>
<tr>
<td>Al</td>
<td>10</td>
<td>Hi</td>
</tr>
<tr>
<td>Al</td>
<td>10</td>
<td>Lo</td>
</tr>
<tr>
<td>Al</td>
<td>1000</td>
<td>Hi</td>
</tr>
<tr>
<td>Al</td>
<td>1000</td>
<td>Lo</td>
</tr>
</tbody>
</table>